Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the immunologic and overall safety associated with
long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less
than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products
other than Alphanate and who have no history of developing either antibody inhibitors to
Factor VIII or nonspecific inhibitors of coagulation.